论文部分内容阅读
目的:探究对系统性红斑狼疮(SLE)患者采用免疫学检验联合检测的临床诊断价值。方法:选取2015年7月-2016年7月本院收治60例SLE患者和同期在本院体检的60例健康人员进行观察,将28例活动期SLE患者作为研究组,将32例非活动期SLE患者作为观察组,60例健康人员作为对照组。对所有观察对象进行免疫学检验[可提取核抗原(ENA)、抗核抗体(ANAS)、抗双链脱氧核糖核酸抗体(ds-DNA)、IgM、IgG、C4、C3、IgA]各项指标联合检测,分析各组检测结果。结果:研究组IgM、IgG、IgA水平明显高于对照组(P<0.05);研究组C4、C3水平明显比对照组低(P<0.05);观察组IgA、IgG水平明显高于对照组(P<0.05);观察组IgM、C4、C3水平与对照组对比差异无统计学意义(P>0.05)。结论:项免疫检测治疗联合检测提高了临床对SLE检测的准确性,减少假阴性结果,对SLE患者的活动性、病情严重程度进行评估,为治疗方案的选择及疗效评估提供诊断依据。
Objective: To explore the clinical diagnostic value of combined immunological test in patients with systemic lupus erythematosus (SLE). Methods: From July 2015 to July 2016, 60 patients with SLE and 60 healthy people in our hospital during the same period were selected for observation. Twenty-eight active SLE patients were selected as the study group. 32 inactive patients SLE patients as observation group and 60 healthy people as control group. Immunoassay was performed on all subjects (ENA, ANAS, ds-DNA, IgM, IgG, C4, C3, IgA) Joint detection, analysis of the test results of each group. Results: The levels of IgM, IgG and IgA in the study group were significantly higher than those in the control group (P <0.05). The levels of C4 and C3 in the study group were significantly lower than those in the control group (P <0.05). IgA and IgG levels in the observation group were significantly higher than those in the control group P <0.05). There was no significant difference in IgM, C4 and C3 levels between the two groups (P> 0.05). Conclusion: The combination of immunoassay and therapies can improve the accuracy of clinical SLE detection, reduce the false negative results, evaluate the activity and severity of SLE patients, and provide the diagnosis basis for the selection of therapeutic regimen and curative effect evaluation.